ReviewAJR. American journal of roentgenology2011
Molecular theranostics: a primer for the imaging professional.
Review in AJR. American journal of roentgenology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 92 citations in OpenAlex.
- Theranostics in the management of colorectal cancer.Discover nano · 2025Review
- Review
- Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation.European journal of medical research · 2024Review
- Theranostic Diagnostics.Results and problems in cell differentiation · 2024Review
- Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications.EJNMMI research · 2023Review
- Article
- Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.Nanotheranostics · 2022Review
- A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.Theranostics · 2021Review
- Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer.Translational oncology · 2020Article
- Production of radiometals in liquid targets.EJNMMI radiopharmacy and chemistry · 2020Review
- Imaging of intranasal drug delivery to the brain.American journal of nuclear medicine and molecular imaging · 2020Review
- An Inhalable Theranostic System for Local Tuberculosis Treatment Containing an Isoniazid Loaded Metal Organic Framework Fe-MIL-101-NH2-From Raw MOF to Drug Delivery System.Pharmaceutics · 2019Article
- Theranostics: is it really a revolution? Evaluating a new term in medicine.Medicine, health care, and philosophy · 2019Article
- Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures.Frontiers in pharmacology · 2019Review
- Medical Imaging: From Roentgen to the Digital Revolution, and Beyond.Rambam Maimonides medical journal · 2018Review
- Silver Nanoparticles: Synthetic Routes, In Vitro Toxicity and Theranostic Applications for Cancer Disease.Nanomaterials (Basel, Switzerland) · 2018Review
- Radiotheranostics in Cancer Diagnosis and Management.Radiology · 2018Review
- Emerging proteomics biomarkers and prostate cancer burden in Africa.Oncotarget · 2017Review
- Advancing theranostics with tumor-targeting peptides for precision otolaryngology.World journal of otorhinolaryngology - head and neck surgery · 2016Review
- Molecular Imaging of Stem Cell Transplantation for Liver Diseases: Monitoring, Clinical Translation, and Theranostics.Stem cells international · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
objectiveA theranostic system integrates some form of diagnostic testing to determine the presence of a molecular target for which a specific drug is intended. Molecular imaging serves this diagnostic function and provides powerful means for noninvasively detecting disease. We briefly review the paradigms rooted in nuclear medicine and highlight recent advances in this field. We also explore how nanometer-sized complexes, called nanomedicines, present an excellent theranostic platform applicable to both drug discovery and clinical use.
conclusionFor imagers, molecular theranostics represents a powerful emerging platform that intimately couples targeted therapeatic entities with noninvasive imaging that yields information on the presence of defined molecular targets before, during, and after cognate therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.